long intergenic non-protein coding RNA 622Genealiases: []
Q-omics provides the consensus-scored LINC00622 profile across patient tissues and cancer cell-line models. LINC00622 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC00622 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, LINC00622 RNA expression shows 17,758 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where LINC00622 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00622 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00622 survival associations across molecular data types. LINC00622 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00622 RNA expression–survival associations across cancer types. High LINC00622 expression shows unfavorable associations in UVM, LIHC, READ, BRCA, ACC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC00622 RNA expression.
This table summarizes LINC00622 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00622. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00622 shows lower tumor expression in LUAD, KIRP, KICH and THCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher LINC00622 RNA expression in tumor versus normal tissue (log2 FC = +0.587, t-test p < 0.001).
This table shows molecular features associated with LINC00622 in patient tissues and cancer cell lines. In patient samples, LINC00622 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
